This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
post featured image

Considering Modifications to Existing FDA Regulatory Incentives to Achieve Greater Racial and Ethnic Diversity in Clinical Trials for Drug Approvals
By Kirsten Axelsen
When clinical trials for new drug approvals fail to adequately represent racial and ethnic groups, there is a lost opportunity to collect...
post featured image

Incentivizing diverse representation in clinical trials: At the Intersection of Science and Law Podcast Series
By Kirsten Axelsen Sarah Schick
Diverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. In this episode, DLA...
post featured image

An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation
By Kirsten Axelsen
Having previously examined the impact of implementing international reference pricing in the United States, Charles River Associates (a...
post featured image

Drug price controls make industry critics feel better, but won’t make people feel healthier
By Kirsten Axelsen
Please note: Article was first published in The American Enterprise Institute for Public Policy Research In Build Back Better, price...
post featured image

Assessing the value of medicine for diverse patients: Implications of a QALY approach for health disparities
By Kirsten Axelsen
Momentum and debate about the application of cost-effectiveness analysis to determine the value and prices of prescription drugs in the...
post featured image

Use of preventive care services declined despite expanded coverage
By Kirsten Axelsen
Key Points: For the privately insured, Medicare, and uninsured populations, the prevalence of the use of preventive care services...